All In MedTech

Device Trial Radar · NCT05597267

The MIRIA Acne Scar Study

Last checked: Nov 20, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Nov 4, 2022

Primary completion

Feb 28, 2025

Study completion Feb 28, 2025

Sponsor

Lead sponsor
AVAVA, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Oct 28, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the performance and efficacy of the AVAVA MIRIA Laser Skin System treatment on acne scars. Participants will be treated with the MIRIA laser at least 4 times with each treatment spaced 4-6 weeks apart. The improvement of acne scars will be evaluated at 1 month and 3 months with a possibility of 6 months evaluation after the fourth treatment.

Conditions

  • Acne Scars - Mixed Atrophic and Hypertrophic

Interventions

  • MIRIA LaserDevice

    4-6 experimental treatments at 4-6 weeks intervals

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ECCA (échelle d'évaluation clinique des cicatrices d'acné) GradingTime frame: 3 months after the final treatment, Optional 6 months after final treatment

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Enchantress Dermatology

    Miami, Florida

  • AVAVA, Inc.

    Waltham, Massachusetts

  • Laser and Skin Surgery Center of New York

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.